Class Action Lawsuit Against Dupixent for T-Cell Lymphoma Mother’s Death Sparks Legal Case Over Hidden Cancer Risks 4X Increased CTCL Risk
Breaking Legal Update: A Tennessee wrongful death lawsuit has thrust Dupixent—used by millions for eczema and asthma—into the national spotlight after a patient’s fatal diagnosis of T-cell lymphoma. Research from 2024 reveals patients with atopic dermatitis treated with dupilumab (Dupixent) face three to four times higher risk of developing cutaneous T-cell lymphoma (CTCL) compared to…









